October 4, 2018 10:03 AM EDT
News Briefing

Na­tal­ie Sacks lands at Har­poon af­ter jump­ing ship at Aduro; Eu­ro­pean biotech fi­nanc­ings surge

John Carroll

Editor & Founder

→ We now know where Na­tal­ie Sacks was head­ed af­ter jump­ing ship at Aduro $ADRO.

The chief med­ical of­fi­cer changed hats but kept the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Bris­tol My­ers, Ky­owa Kirin dis­close lay­offs

Am­gen an­nounces hold on Phase 1 obe­si­ty can­di­date, pipeline cuts

Eye­Point shares more mid-stage da­ta for ther­a­py try­ing to com­pete with Re­gen­eron's Eylea

No­vo Nordisk is feel­ing the com­pe­ti­tion from com­pound­ed GLP-1s, ex­ec says

Pfiz­er says it has at least $10B avail­able for deals in 2025, with a fo­cus on pipeline

GSK de­fi­ant against vac­cine chal­lenges, will pri­or­i­tize oth­er growth ar­eas

A service from the Financial Times